Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.3.16 (
calcineurin
)
17,112
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Using
AMP deaminase
(
AMP aminohydrolase
;
EC 3.5.4.6
) purified from rabbit left-ventricular heart tissue, we report direct investigation of the potential for cardiac
AMP deaminase
activity to be regulated by kinase-mediated phosphorylation. Rabbit heart
AMP deaminase
served as a substrate for Ca2+/phospholipid-dependent protein kinase (protein kinase C; PKC) exclusively; no other mammalian protein kinase phosphorylated the enzyme. PKC-dependent
AMP deaminase
phosphorylation was rapid, linear with respect to time and the concentrations of PKC and
AMP deaminase
in the reaction, and inhibitable by staurosporine. Upon phosphorylation, the apparent Km of cardiac
AMP deaminase
decreased from 5.6 mM to 1.2 mM, without effect on the Vmax. Whether phosphorylated or not, rabbit heart
AMP deaminase
was inhibited by 1.0 mM GTP, which decreased the Vmax. by approximately 50% in each case. PKC-dependent phosphorylation of cardiac
AMP deaminase
did not alter the enzyme's allosterism toward millimolar ATP or ADP: both nucleotides at 1.0 mM concentration decreased the apparent Km to approximately 0.5 mM. Treatment of cardiac phospho-
AMP deaminase
with either the
protein phosphatase
calcineurin
or alkaline phosphatase generated a dephosphorylated form which displayed molecular and kinetic properties identical with those of the originally isolated enzyme. These data raise the possibility that a phosphorylation-dephosphorylation mechanism may regulate flux through
AMP deaminase
in the heart under pathological conditions, such as myocardial ischaemia, characterized by PKC activation and adenylate depletion.
...
PMID:Modulation of mammalian cardiac AMP deaminase by protein kinase C-mediated phosphorylation. 838 71